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Objective (1) To determine the prevalence of antidepressant
utilisation before, during, and after pregnancy, (2) to determine
switches, dosages, and classes of antidepressant used during
pregnancy, and (3) to identify factors associated with their use at
the beginning and at the end of pregnancy.
Design Retrospective longitudinal cohort.
Setting The ‘Medication and Pregnancy’ cohort was used for this
study. This cohort was built by the linkage of three administrative
databases (Re ´gie de l’Assurance Maladie du Que ´bec [RAMQ],
Med-E ´cho, and l’Institut de la Statistique du Que ´bec).
Population All pregnancies occuring in Quebec between January 1
1998 and December 31 2002.
Methods Date of entry in the cohort was the ﬁrst day of gestation.
To be eligible for this study, women had to be (1) 15–45 years old
at cohort entry and (2) covered by the RAMQ drug plan for at
least 12 months before, during, and at least 12 months after
pregnancy. Antidepressant users were defined as those receiving at
least one antidepressant before, during, or after pregnancy,
depending on the time period analysed. Logistic regression models
were used to identify factors associated with receiving an
antidepressant either at the beginning or at the end of pregnancy.
Main outcome measures To determine the prevalence and
predictors associated with the use of antidepressants.
Results A total of 97 680 women met inclusion criteria. The
prevalence rates signiﬁcantly declined during the ﬁrst trimester
compared with before pregnancy (3.7 versus 6.6%, P < 0.01).
During pregnancy, antidepressants were used under the
recommended daily dosage 7.7% of the time, and 4.7% of
women switched to another class of antidepressant. Factors
signiﬁcantly associated with antidepressant utilisation on the ﬁrst
day of gestation (P < 0.05) were older maternal age, being on
welfare, and calendar year; receiving at least six different types of
medications other than antidepressants, having at least two
different prescribers, having at least three visits to the physician,
and having at least one diagnosis of depression in the year
before pregnancy also increased the odds of having an
antidepressant. Similar predictors were found at the end of
pregnancy.
Conclusions Our ﬁndings indicate that antidepressant utilisation
declines once pregnancy is diagnosed.
Keywords Antidepressants, dosage, predictors, pregnancy,
prevalence, switch.
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Introduction
Depression is a common disorder in women of childbearing
age. Indeed, up to 9% of women experience depression dur-
ing pregnancy.1,2 Nevertheless, antidepressant use during the
gestational period remains a controversial topic. One report
on mental health suggests that physicians may often under-
prescribe or stop antidepressants at the time of conception
and during pregnancy.3 This may be a consequence of the
concern over the safety of these agents in pregnant women
and the risks they may pose to the fetus. In fact, since the
thalidomide disaster in 1962, antidepressants like other med-
ications used during pregnancy have often been associated in
the mind of the public with congenital malformations or
other severe complications in newborns without any scientiﬁc
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known to be 1.5–3%.6 Therefore, a substantial number of
children could be born with some birth defects without the
inﬂuence of maternal exposure to medications. This notion
may be frequently misunderstood by health providers and
the general population. However, there are reports of antide-
pressant drug use and teratogenic effects, for example recent
associations between ﬁrst-trimester exposure to selective sero-
tonin reuptake inhibitors (SSRIs) and cardiac malformations
or persistent pulmonary hypertension of the newborn, which
have raised justiﬁable concerns7,8 that require further study.
Discontinuation of antidepressant use during pregnancy is
also associated with relapse of depression and withdrawal
symptoms, which is not optimal for the mother and her
fetus9. Even after reinstating the antidepressant, it may take
several weeks for the depression to be controlled.10 Further-
more, during pregnancy, psychological stress has been asso-
ciated with poor perinatal outcomes.11,12 Therefore, it seems
critical enough for clinicians treating women of childbearing
age to have information available, which may guide them
in treatment decisions during pregnancy, as they negotiate
the delicate balance between the use of medications, such
as psychotropics and the risks of undertreating depressive
disorders.13
To our knowledge, there have been no studies that have
speciﬁcally investigated the prevalence and trends of antide-
pressant use, before, during, and after pregnancy. Therefore,
the purpose of this study was: (1) to determine the prevalence
of antidepressant use before, during, and after pregnancy,
(2) to determine the percentage of switches during the ﬁrst
trimester of pregnancy, to list the dosages and classes of anti-
depressant used during pregnancy, and (3) to identify pre-
dictors associated with antidepressant use on the ﬁrst day of
gestation and at the end of pregnancy.
Methods
We used three administrative databases of the Province of
Quebec: la Re ´gie de l’Assurance Maladie du Que ´bec (RAMQ),
Med-E ´cho, and Le ﬁchier des e ´ve ´nements de ´mographiques
du Que ´bec (birth and death registries) of l’Institut de la Sta-
tistique du Que ´bec (ISQ). The RAMQ database contains
information on medical services (diagnoses and procedures)
received by all Quebec residents. All diagnoses are classiﬁed
according to the International Classiﬁcation of Diseases, Ninth
Revision (ICD-9).14 Although RAMQ covers all Quebec resi-
dents for the cost of physician visits, hospitalisations, and
procedures, it only covers a portion of residents for the cost
of medications. The RAMQ drug plan covers individuals 65
years and older, recipients of social assistance (welfare recip-
ients), and workers and their families (adherents) who do not
have access to a private drug insurance programme, account-
ing for approximately 43% of the overall Quebec popu-
lation.15 It is also estimated that 30% of women between
15 and 45 years of age in Quebec are covered by the RAMQ
drug plan for their medication (RAMQ data). The Med-E ´cho
database is a provincial database, which records acute care
hospitalisation data for all Quebec residents; it also records
gestational age for planned abortions, miscarriages, and deliv-
eries. ISQ provides demographic information on the mother,
father, and baby, as well as birthweight and gestational age for
live births and stillbirths.
The RAMQ and Med-E ´cho databases have often been used
in the past for epidemiological research.16–18The ISQ database
has also been used in epidemiological studies.19 Data recorded
in the medication database of the RAMQ have been suitably
evaluated and found to be comprehensive and valid.20 The
same was found for medical diagnoses recorded in the
Med-E ´cho database.21
The RAMQ, Med-E ´cho, and ISQ databases were linked to-
gether to createthe‘Medications andPregnancy’ cohortwhich
contains data on all pregnancies that occurred in Quebec
between 1 January 1998 and 31 December 2002. The linkage
between the three databases was performed using women’s
‘Numero d’Assurance Maladie’, which is the unique identiﬁer
for all Quebec residents (RAMQ and Med-E ´cho), and using
mothers and babies dates of birth, ﬁrst names, and family
names (RAMQ and ISQ). This cohort is composed of women
with a diagnosis or procedure code related to pregnancy.
Within the ‘Medications and Pregnancy’ cohort, women
meeting the following eligibility criteria were included in this
study: theyhad tobe (1) between 15and 45 years of age on the
date of entry in the cohort deﬁned as the ﬁrst day of gestation
and (2) continuously insured by the RAMQ drug plan for at
least 12 months before the ﬁrst day of gestation, during the
pregnancy, and for at least 12 months after the end of preg-
nancy. The end of pregnancy was deﬁned as the calendar date
of a planned abortion, miscarriage, or delivery. If a woman
had more than one pregnancy between 1998 and 2002, the
ﬁrst pregnancy meeting eligibility criteria was included for
analysis.
The prevalence of antidepressant use during the ‘12 months
before pregnancy’ was calculated by dividing the number of
women receiving at least one antidepressant in this 12-month
period by the total number of women in the cohort. The same
calculations were performed for the time period ‘during preg-
nancy’ and for the time period ‘12 months after the end of
pregnancy’. In addition, the prevalence of antidepressant use
in the ﬁrst trimester (£14 weeks of gestational age), second
trimester (>14 to £26 weeks of gestational age), and third
trimester (>26 weeks of gestational age) of pregnancy was
calculated by dividing the number of women ﬁlling at least
one antidepressant prescription in the respective trimesters by
the number of women in the study at that time (depending on
the outcome of the pregnancy, some women were counted in
the denominator only in the ﬁrst or second trimester). When
Ramos et al.
1056 ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecologythe duration of a prescription overlapped between trimesters,
women were deﬁned as exposed in both time periods. The
prevalence of antidepressant use according to pharmaco-
logical class and type stratiﬁed by trimester was calculated
in the same manner.
For each dispensed prescription of an antidepressant,
the daily dosage was calculated. This daily dosage was then
compared with the optimal range recommended by The Public
Health Agency of Canada.22 Since lower dosages are often pre-
scribed at the initiation of a treatment and thus could decrease
the overall daily dosage, we used the lower range of what is
considered the minimum threshold of pharmacological efﬁ-
cacy.22 The daily dosage for each prescription could fall into
one of the following three categories: optimal dosage, under-
dosage, or overdosage. For a given antidepressant, the percent-
age of prescriptions with optimal dosage was calculated by
dividing all prescriptions that were optimally prescribed by
the total number of prescriptions. The same calculation was
performed to determine the percentage of prescriptions with
sub-dosage and overdosage. We restricted these calculations to
womenwithat least one diagnosis of major depressive disorder
(ICD-9 codes: 296.2 and 296.3)14 either during pregnancy or
during the 12 months before pregnancy. This was necessary
since these dosage recommendations are intended for women
with major depressive disorders.
We determined the percentage of subjects who had at least
one switch from one class or type of antidepressant to another
in the ﬁrst trimester.
Women were considered exposed to antidepressants on the
ﬁrst day of gestation and at the end of pregnancy if they ﬁlled
a prescription or if the duration of a prescription overlapped
on these days. In addition, we allowed a 7-day grace period
between consecutive prescriptions of antidepressants, and
thus, women were considered exposed if the ﬁrst day of ges-
tation or end of pregnancy fell during this grace period.
The following variables were considered as potential pre-
dictors of receiving at least one antidepressant on the ﬁrst day
of gestation and were measured on this day: maternal age,
maternal place of residence (urban versus rural), maternal
RAMQ drug plan status (adherent versus welfare recipient),
and calendar year. The following variables were also consid-
ered as potential predictors of receiving at least one anti-
depressant on the ﬁrst day of gestation and were measured
in the year before pregnancy: number of different types of
medications used other than antidepressants, number of dif-
ferent prescribers for all medications, planned abortions or
miscarriages, number of visits to the physician, visits to the
emergency department and/or hospitalisations, and diagno-
sis of depression (ICD-9 codes: 296.x; 300.4; 309; 311).23
Predictors of antidepressant use at the end of pregnancy
were determined only for women who had delivered a baby
(live birth and stillbirth) and thus excluded for women whose
pregnancies resulted in planned abortions or miscarriages.
As our cohort spanned a 5-year period, we controlled for
any time trend in prescribing practices by adjusting the esti-
mates for the calendar year on the ﬁrst day of gestation.
This study was approved by the Sainte-Justine Hospital
Ethics Committee, and by the Commission d’Acce `sa ` l’Infor-
mation du Que ´bec, the agency granting ethics clearance for
the use of linked administrative data.
Statistical analysis
Descriptive statistics were used to summarise the character-
istics of the study population. McNemar’s test was used to
compare the prevalence of antidepressant use before versus
during the ﬁrst trimester of pregnancy and before versus after
pregnancy. Unconditional logistic regression models were
performed to identify and quantify predictors of antidepres-
sant use on the ﬁrst day and on the last day of gestation,
separately. All analyses were two-tailed, and P £ 0.05 was
considered signiﬁcant. SAS version 8.2 (SAS Institute Inc.,
Cary, NC, USA) was used to perform the analyses.
Results
Of the 152 107 women in the ‘Medication and Pregnancy’
cohort with pregnancies between 1 January 1998 and 31
December 2002, a total of 97 680 met the eligibility criteria
and were included in the study. The mean (SD) age of the
cohort was 27.4 (6.1) years, and the majority of women were
adherents of the RAMQ drug plan (65.0%) and urban dwell-
ers (79.9%) on the ﬁrst day of gestation.
Of the 97 680 pregnancies, 56 981 (58.3%) ended with a
delivery, whereas the remaining 40 699 (41.7%) resulted in
planned abortions (36 015 [36.9%]) or miscarriages (4684
[4.8%]).Womenwhohadapregnancythatendedinadelivery,
compared with women who had a planned abortion or had
a miscarriage were older (28.2 [5.6] years versus 27.6 [6.7]
years, P < 0.01), were more likely to be adherents of the RAMQ
drug plan (68.7 versus 59.0%, P < 0.01) and were less likely to
be living in urban areas (76.6 versus 84.6%, P <0 . 0 1 ) .
The prevalence of antidepressant use during the 12 months
before the ﬁrst day of gestation and during the 12 months
after the end of pregnancy was 6.6 and 7.0%, respectively
(P < 0.01). Rates of antidepressant use declined signiﬁcantly
during the ﬁrst trimester compared with before pregnancy
(3. 7 versus 6.6%, P < 0.01) and continued to decrease during
the second (1.6%) and the third trimesters (1.1%) (Table 1).
During the ﬁrst trimester of pregnancy, among antide-
pressant users (n = 3587), the three most prevalent antide-
pressant classes used were SSRIs (2607 [64.4%]), serotonin and
norepinephrine reuptake inhibitors (SNRIs) (497 [12.3%]),
and tricyclics (491 [12.1%]) (Table 2). More speciﬁcally,
paroxetine (1385 [34.2%]) and sertraline (515 [12.7%]) were
the most frequently used SSRIs, whereas venlafaxine (497
[12.3%])was themost frequentlyused SNRI,andamitriptyline
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ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology 1057(349 [8.6%]) was the most frequently used tricyclic (Table 2).
The use of nonhydrazine reversible monoamine oxidase inhib-
itor (MAOIs) was minimal (3 [0.1%]) (Table 2).
A total of 349 women had received a diagnosis of major
depressive disorder either during pregnancy or during the
12 months before pregnancy. For the following drugs, all
prescriptions were at optimal dosage: bupropion, clomip-
ramine, doxepin, desipramine, ﬂuvoxamine, and nortriptyline
(Table 3). Paroxetine was at optimal dosage in 99.5% of
women and ﬂuoxetine in 99.4% of women. In contrast, trazo-
done, amitriptyline, and sertraline were the antidepressants
with the highest percentage of prescriptions with sub-dosage
during pregnancy (40.3, 26.3, and 12.7%, respectively)
(Table 3). No subjects had prescriptions that were considered
overdosed according to guidelines.
Among antidepressant users on the ﬁrst day of gestational
age (n = 2442), 4.7% of women switched to another class of
antidepressants at least once during the ﬁrst trimester. SSRIs
were the class of antidepressants to which women switched to
the most (40 [1.6%]), followed by the serotonin modulators
(30 [1.2%]), and SNRIs (24 [1.0%]). More speciﬁcally, 6.1%
of women switched to another type of antidepressant at least
once during the ﬁrst trimester. Paroxetine (24 [1.0%]) and
venlafaxine (24 [1.0%]) were the types of antidepressants to
which women switched to the most.
The results concerning predictors of antidepressant use at
the beginning of pregnancy are shown in Table 4. Factors
signiﬁcantly associated with antidepressant use on the ﬁrst
day of gestation and measured on this day were older mater-
nal age, being on welfare, and calendar year. Having received
at least six different types of medications other than anti-
depressants, having at least two different prescribers, having
a higher number of visits to the physician, and having at least
one diagnosis of depression in the year prior to the ﬁrst day of
gestation were also signiﬁcantly associated with antidepres-
sant use on the ﬁrst day of gestation. In contrast, having at
least one visit to the emergency department or one hospital-
isation decreased the probability of using an antidepressant
on the ﬁrst day of gestation.
Among women with a delivery (live birth or stillbirth),
predictors of antidepressant use at the end of pregnancy were
also identiﬁed (Table 5). Predictors were similar to those
found at the beginning of pregnancy.
Discussion
To our knowledge, this is the ﬁrst study to longitudinally
investigate the prevalence of antidepressant use before, during,
and after pregnancy. In addition, it is the ﬁrst study to deter-
mine the percentage of switches and the dosages and classes of
antidepressants used during pregnancy. Furthermore, predic-
tors of antidepressant use on the ﬁrst day and onthe last day of
gestation were identiﬁed. Antidepressant use was reduced
by nearly half during the ﬁrst trimester (3.7 versus 6.6%,
P £ 0.01), only to increase during the postpartum period
(7.0 versus 6.6%, P £ 0.01). These data conﬁrm that health-
care providers remain cautious in prescribing antidepres-
sants during pregnancy or that the women themselves
hesitate to take these drugs during this time period. These
results are consistent with a recent study, which found that
the prescription rates of most medications used to treat
chronic diseases decrease during pregnancy, especially those
for antidepressants.24
The three most prevalent classes of antidepressants
prescribed during pregnancy were SSRIs (64.4%), SNRIs
(12.3%), and tricyclics (12.1%). The use of MAOIs was
limited (0.1%). Although until now no deﬁnitive data were
available, it has been assumed that the use of antidepres-
sants during pregnancy reﬂects usage patterns in the general
population.25 Indeed, in the general population, SSRIs have
been the most widely used antidepressant because of their
established efﬁcacy, their milder adverse effect proﬁle, and
Table 1. Prevalence of antidepressant utilisation before, during, and after pregnancy
Period Number of
antidepressant users
Total number of
women*
Percent
(95% CI)
During the 12 months before the ﬁrst day of gestation 6427 97 680 6.6 (6.4–6.7)
During pregnancy
First trimester (14 weeks) 3587 97 680 3.7 (3.6–3.8)**
Second trimester (.14 to 26 weeks) 1256 80 164 1.6 (1.5–1.6)
Third trimester (.27 weeks) 618 56 578 1.1 (1.0–1.2)
During the 12 months after the end of pregnancy*** 6816 97 680 7.0 (6.8–7.1)****
*Depending on the gestational age at the end of pregnancy, some women were not included in the denominators for the prevalence of use
in the second or third trimesters.
**P 5 0.01—Comparing the 12 months before the first day of gestation to first trimester.
***The end of pregnancy was deﬁned as a planned abortion, a miscarriage, or a delivery.
****P 5 0.01—Comparing the 12 months before the first day of gestation to the 12 months after the end of pregnancy.
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such as venlafaxine, bupropion, and mirtazapine, as well as
tricyclic antidepressants, have been preferred by healthcare
providers. In contrast, the safety concerns regarding drug
and food interactions have limited the use of MAOIs.25 Our
results seem to conﬁrm these ﬁndings during pregnancy.
However, this utilisation pattern may soon change, given
the recent warnings on gestational use of paroxetine and neg-
ative outcomes on the newborn.26,27
Our data indicate that antidepressants are prescribed
according to published recommendations 92.3% of the time
during pregnancy. More precisely, antidepressants are pre-
scribed under the recommended dosage 7.7% of the time
and never over the recommended dosage during the
Table 2. Class and type of antidepressants used during the ﬁrst, second, and third trimesters
First trimester
(•14 weeks) (n 5 3587)*
Second trimester
(>14 to • 26 weeks) (n 5 1256)*
Third trimester
(>26 weeks) (n 5 618)*
SSRIs, n (%)
Citalopram 304 (7.5) 103 (7.5) 39 (6.0)
Fluoxetine 300 (7.4) 118 (8.6) 64 (9.9)
Fluvoxamine 103 (2.6) 38 (2.8) 20 (3.1)
Paroxetine 1385 (34.2) 504 (36.8) 270 (41.7)
Sertraline 515 (12.7) 180 (13.2) 87 (13.5)
Total 2607 (64.4) 943 (68.9) 480 (74.2)
Tricyclics, n (%)
Amitriptyline 349 (8.6) 87 (6.4) 42 (6.5)
Clomipramine 23 (0.6) 7 (0.5) 2 (0.3)
Desipramine 21 (0.5) 10 (0.7) 5 (0.8)
Doxepin 47 (1.2) 19 (1.4) 11 (1.7)
Imipramine 17 (0.4) 9 (0.7) 6 (0.9)
Nortriptyline 18 (0.4) 6 (0.4) 3 (0.5)
Trimipramine 16 (0.4) 7 (0.5) 3 (0.5)
Total 491 (12.1) 145 (10.6) 72 (11.2)
Tetracyclics, n (%)
Amoxapine 0 (0.0) 0 (0.0) 0 (0.0)
Maprotiline 1 (0.0) 0 (0.0) 0 (0.0)
Total 1 (0.0) 0 (0.0) 0 (0.0)
MAOIs, n (%)
Phenelzine 2 (0.1) 0 (0.0) 0 (0.0)
Tranylcypromine 1 (0.0) 0 (0.0) 0 (0.0)
Total 3 (0.1) 0 (0.0) 0 (0.0)
Reversible inhibitors of monoamine oxidase type A, n (%)
Moclobemide 11 (0.3) 1 (0.1) 0 (0.0)
Total 11 (0.3) 1 (0.1) 0 (0.0)
Dopamine and norepinephrine reuptake inhibitors, n (%)
Bupropion 87 (2.2) 30 (2.2) 7 (1.1)
Total 87 (2.2) 30 (2.2) 7 (1.1)
Tetracyclic piperazino-azepine, n (%)
Mirtazapine 10 (0.3) 2 (0.2) 1 (0.2)
Total 10 (0.3) 2 (0.2) 1 (0.2)
Serotonin modulators, n (%)
Nefazodone 90 (2.2) 27 (2.0) 9 (1.4)
Trazodone 248 (6.1) 81 (5.9) 25 (3.9)
Total 338 (8.3) 108 (7.9) 34 (5.3)
SNRIs, n (%)
Venlafaxine 497 (12.3) 140 (10.2) 53 (8.2)
Total 497 (12.3) 140 (10.2) 53 (8.2)
Percentages may not add up to 100% due to rounding. Groups are not mutually exclusive since a woman could have received more than one
antidepressant.
*Number of women who received at least one antidepressant during the ﬁrst, second, or third trimester, respectively.
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during pregnancy are important. Higher dose requirements
for most antidepressants are necessary to avoid subtherapeu-
tic blood concentrations.28
Only 6.1% of women switched from one antidepressant to
another during the ﬁrst trimester, whereas the majority of
women discontinued their current antidepressant. It would
have been expected that more women would have switched
from one antidepressant to another instead of discontinuing
their treatment. This fact reinforces the idea that physicians or
women prefer terminating an antidepressant treatment rather
than selecting another one with a better safety proﬁle. Instead,
careful treatment planning should be in place for those
women on antidepressants who plan to conceive or who
become pregnant.
We found several predictors using an antidepressant at the
beginning and at the end of pregnancy. Both models indicated
that a higher number of prescribers before and during preg-
nancy, a higher number of visits to the physician before preg-
nancy, and having a diagnosis of depression before or during
pregnancy increased the probability of using antidepressants
on the ﬁrst day and on the last day of gestation. These results
suggest that subjects who initiated or continued receiving
antidepressants at these times were those women who were
likely to be less healthy than those who did not initiate or
discontinued using them. In addition, having a diagnosis of
depression was associated with receiving an antidepressant,
indicating that antidepressants are more likely used for the
indication for which they were intended. We found that
48.9% of women had received a diagnosis of depression in
the year prior to the ﬁrst day of gestation. This probably
represents an underestimation since diagnosis could have
been made before the study period. We also found in both
models that being an adherent to the RAMQ drug plan (ver-
sus a welfare recipient) decreased the likelihood of receiving
an antidepressant. This could partly be explained by the fact
Table 3. Dosage characteristics during the gestational period
Antidepressant Optimal dosage*, n (%) Sub-dosage*, n (%) Overdosage*, n (%) Range according
to published guidelines22
Amitriptyline 28 (73.7) 10 (26.3) 0 (0.0) 25–300
Amoxapine** — — — Not available
Bupropion 89 (100.0) 0 (0.0) 0 (0.0) 100–300
Citalopram 149 (97.4) 4 (2.6) 0 (0.0) 10–60
Clomipramine 26 (100.0) 0 (0.0) 0 (0.0) 25–300
Desipramine 63 (100.0) 0 (0.0) 0 (0.0) 25–300
Doxepin 3 (100.0) 0 (0.0) 0 (0.0) 25–300
Fluoxetine 156 (99.4) 1 (0.6) 0 (0.0) 10–80
Fluvoxamine 27 (100.0) 0 (0.0) 0 (0.0) 50–300
Imipramine*** N/A N/A N/A 25–300
Maprotiline*** N/A N/A N/A 30–225
Mirtazapine** — — — Not available
Moclobemide** — — — Not available
Nefazodone 26 (96.3) 1 (3.7) 0 (0.0) 100–600
Nortriptyline 7 (100.0) 0 (0.0) 0 (0.0) 10–200
Paroxetine 373 (99.5) 2 (0.5) 0 (0.0) 10–60
Phenelzine** — — — Not available
Sertraline 199 (87.3) 29 (12.7) 0 (0.0) 50–225
Tranylcypromine** — — — Not available
Trazodone 80 (59.7) 54 (40.3) 0 (0.0) 75–600
Trimipramine*** N/A N/A N/A 25–300
Venlafaxine 33 (89.2) 4 (10.8) 0 (0.0) 75–225
N/A, Nonapplicable.
*The percentage of prescriptions with optimal dosage, for a given antidepressant, was calculated by dividing all prescriptions that were
optimally prescribed by the total number of prescriptions. The same calculation was performed to determine the percentage of prescriptions
with sub-dosage and overdosage. These percentages were restricted to women who had at least one diagnosis of major depressive disorder
(ICD-9 codes: 296.2 and 296.3) in any period prior to receiving the antidepressant.
**The range for the following antidepressants were not available in published guidelines: amoxapine, mirtazapine, moclobemide, phenelzine,
and tranylcypromine.
***The following antidepressants were not prescribed in our cohort for women who had at least one diagnosis of major depressive disorder
during the gestational period: imipramine, maprotiline, and trimipramine.
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compared with adherents, are more likely to have depres-
sion.29 Indeed, Murphy et al.29 have found an association
between socio-economic status and depression.
This study included a large sample of pregnant women, and
thus, we were able to study a wide variety of characteristics
in women that could predict antidepressant use before and
during pregnancy. Administrative databases have the great
potential of providing accurate drug dispensing history
throughout pregnancy and are not affected by recall bias.
Such databases give full details on the names, doses, and
quantities of medications dispensed thus offering information
that is almost impossible to obtain by questioning women
who have to recall their use of medications over an extended
period of time.30–33
The use of administrative databases has some limitations.
Data are not available on women who do not use medical
services during pregnancy or who give birth in a setting out-
side the hospital. However, given the free universal healthcare
system in place in Quebec, we expect the effect of these
women on our results to be minimal. In addition, data are
not available on medications dispensed over-the-counter
without a prescription. This was not problematic in the
present study because all antidepressants require a written
prescription. An unresolved problem is that we do not have
data on the number of women who discontinued their anti-
depressant therapy to initiate herbal treatments for depres-
sion, such as St John’s Wort.
The prevalence of antidepressant use was calculated on
the basis of the drugs dispensed to study subjects and does
notreﬂecttheactualintake.However,ourstudyhastheadvan-
tageoverﬁeldstudies,whichusuallyrelyonself-reporteddrug
histories and therefore are prone to recall bias.
In the calculation of optimal dosage, sub-dosage, and over-
dosage, we used guidelines for treating depression during
pregnancy published in 2003. Our cohort spanned a 5-year
period, 1998–2002, and thus, we applied 2003 guidelines to
earlier years when official recommendations on how to
Table 4. Predictors of antidepressant use on the ﬁrst day of gestation
Users on the ﬁrst
day of gestation
(n 5 2442)
Nonusers on the ﬁrst
day of gestation (n 5 95 238)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)*
On the ﬁrst day of gestation
Maternal age, years (mean, SD) 29.8 (6.4) 27.34 (6.1) 1.07 (1.06–1.07) 1.07 (1.06–1.07)
Urban dwellers, n (%) 1993 (81.6) 76 086 (79.9) 1.12 (1.01–1.24) 0.94 (0.84–1.05)
Welfare, n (%) 1200 (49.1) 31 808 (34.6) 1.82 (1.68–1.98) 1.41 (1.29–1.54)
During the 12 months before the ﬁrst day of gestation
Number of different prescribers, n (%)
1 273 (11.2) 50 012 (52.5) 1.00 1.00
2 2169 (88.8) 45 226 (47.5) 8.78 (7.74–9.97) 3.92 (3.36–4.57)
Number of different medications used other than antidepressants, n (%)
0–2 692 (28.3) 62 688 (65.8) 1.00 1.00
3–5 936 (38.3) 24 523 (25.8) 3.46 (3.13–3.82) 1.13 (1.00–1.27)
6 814 (33.3) 8027 (8.4) 9.19 (8.28–10.20) 1.79 (1.57–2.05)
Abortion/miscarriage, n (%) 45 (1.8) 2006 (2.1) 0.87 (0.65–1.18) 0.83 (0.60–1.13)
Number of visits to a physician, n (%)
0–2 172 (7.0) 33 057 (34.7) 1.00 1.00
3–5 392 (16.1) 25 664 (27.0) 2.94 (2.45–3.51) 1.52 (1.26–1.83)
6 1878 (76.9) 36 517 (38.3) 9.88 (8.45–11.56) 2.42 (2.03–2.89)
Emergency department visit/hospitalisation,
n (%)
482 (19.7) 13 919 (14.6) 1.44 (1.30–1.59) 0.72 (0.64–0.80)
Diagnosis of depression**, n (%) 1193 (48.9) 4172 (4.4) 20.85 (19.15–22.70) 11.59 (10.57–12.72)
Calendar year on the ﬁrst day of gestation, n (%)
1 January 1998 to 31 December 1998 438 (17.9) 25 267 (26.5) 1.00 1.00
1 January 1999 to 31 December 1999 519 (21.25) 22 098 (23.2) 1.36 (1.19–1.54) 1.34 (1.17–1.54)
1 January 2000 to 31 December 2000 525 (21.50) 18 568 (19.5) 1.63 (1.44–1.85) 1.59 (1.38–1.82)
1 January 2001 to 31 December 2001 550 (22.5) 16 788 (17.6) 1.89 (1.66–2.15) 1.93 (1.68–2.21)
1 January 2002 to 31 December 2002 410 (16.8) 12 517 (13.1) 1.89 (1.65–2.17) 1.86 (1.60–2.16)
Percentages may not add up to 100% due to rounding.
*Adjusted for the covariates in the table.
**ICD-9 codes: 296.x, 300.4, 309, 311.
Antidepressant use in a cohort of pregnant women
ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology 1061prescribe antidepressants during pregnancy were not avail-
able. Despite the limitation of using the 2003 guidelines, we
were able to determine how appropriately physicians pre-
scribed antidepressants during pregnancy in the absence of
guidelines. In fact, it should be noted that the 2003 guidelines
were based on publications that were available in the years
prior or during the time period of this study. We found that
physicians tended to prescribe suboptimal dosages during
pregnancy, which may be related to the fear of potential neg-
ative effects on the fetus.
Table 5. Predictors of antidepressant use on the last day of gestation
Users on the last
day of gestation
(n 5 452)
Nonusers on the last
day of gestation
(n 5 56 529)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)*
At the end of pregnancy
Maternal age, years (mean, SD) 30.2 (5.9) 28.2 (5.6) 1.06 (1.05–1.08) 1.06 (1.04–1.07)
Urban dwellers, n (%) 354 (78.3) 43 216 (76.5) 1.11 (0.89–1.39) 0.90 (0.71–1.15)
Welfare, n (%) 241 (53.3) 17 769 (32.7) 2.35 (1.96–2.83) 1.39 (1.12–1.71)
During the 12 months before the ﬁrst day of gestation
Number of different prescribers, n (%)
1 74 (16.4) 29 960 (53.0) 1.00 1.00
2 378 (83.6) 26 569 (47.0) 5.76 (4.49–7.39) 1.72 (1.24–2.39)
Number of different medications use other than antidepressants, n (%)
0–2 136 (30.1) 37 479 (66.3) 1.00 1.00
3–5 162 (35.8) 14 419 (25.5) 3.10 (2.46–3.89) 0.95 (0.71–1.26)
6 154 (34.1) 4631 (8.2) 9.16 (7.26–11.57) 1.09 (0.78–1.52)
Abortion/miscarriage, n (%) 7 (1.6) 864 (1.5) 1.01 (0.48–2.15) 1.10 (0.51–2.40)
Number of visits to a physician, n (%)
0–2 43 (9.5) 19 602 (34.7) 1.00 1.00
3–5 78 (17.3) 15 058 (26.6) 2.36 (1.63–3.43) 1.35 (0.91–1.99)
6 331 (73.2) 21 869 (38.7) 6.90 (5.02–9.49) 1.66 (1.15–2.41)
Emergency department visit/hospitalisation, n (%) 98 (21.7) 8265 (14.6) 1.62 (1.29–2.02) 0.84 (0.65–1.08)
Diagnosis of depression**, n (%) 187 (41.4) 2401 (4.3) 15.91 (13.14–19.27) 4.36 (3.44–5.54)
Between the ﬁrst day of gestation and the end of pregnancy
Number of different prescribers, n (%)
1 67 (14.8) 38 784 (68.6) 1.00 1.00
2 385 (85.2) 17 745 (31.4) 12.56 (9.68–16.29) 5.17 (3.79–7.06)
Number of different type of medications use other than antidepressants, n (%)
0–2 163 (36.1) 44 791 (79.2) 1.00 1.00
3–5 167 (37.0) 9781 (17.3) 4.69 (3.78–5.83) 1.12 (0.87–1.45)
6 122 (27.0) 1957 (3.5) 17.13 (13.49–21.76) 2.12 (1.55–2.89)
Number of prenatal visits, n (%)
0–5 100 (22.12) 11 222 (19.85) 1.00 1.00
6–11 239 (52.88) 31 275 (55.33) 0.86 (0.68–1.08) 0.84 (0.65–1.09)
12 113 (25.0) 14 032 (24.82) 0.90 (0.69–1.18) 0.89 (0.66–1.21)
Emergency department visit/hospitalisation, n (%) 393 (87.0) 49 808 (88.1) 0.90 (0.68–1.18) 1.04 (0.76–1.41)
Diagnosis of depression**, n (%) 139 (30.8) 1001 (1.8) 24.64 (19.99–30.38) 5.21 (4.02–6.74)
Gestational age
,37 weeks 57 (12.6) 4050 (7.2) 1.00 1.00
37 weeks 395 (87.4) 52 479 (92.8) 0.54 (0.40–0.71) 0.77 (0.56–1.05)
Calendar year on the ﬁrst day of gestation, n (%)
1 January 1998 to 31 December 1998 66 (14.6) 14 631 (25.9) 1.00 1.00
1 January 1999 to 31 December 1999 99 (21.9) 13 329 (23.6) 1.65 (1.21–2.25) 1.66 (1.19–2.30)
1 January 2000 to 31 December 2000 101 (22.4) 11 171 (19.8) 2.00 (1.47–2.74) 1.96 (1.41–2.72)
1 January 2001 to 31 December 2001 109 (24.1) 9984 (17.7) 2.42 (1.78–3.29) 2.60 (1.88–3.61)
1 January 2002 to 31 December 2002 77 (17.0) 7414 (13.1) 2.30 (1.66–3.20) 2.36 (1.65–3.36)
Percentages may not add up to 100% due to rounding.
*Adjusted for the covariates in the table.
**ICD-9 codes: 296.x, 300.4, 309, 311.
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abortions and miscarriages, but it was not always easy to
distinguish between them. This may have resulted in mis-
classiﬁcation, which could explain the low percentage of
miscarriages (4.8%).Finally, drugs dispensed during hospital-
isations are not included in the RAMQ database. As such, it
could explain why having a hospitalisation decreased the like-
lihood of using an antidepressant on the ﬁrst day of gestation.
The RAMQ database provides information on welfare
recipients and on adherents of the RAMQ drug plan only
and not on individuals who are covered by private drug insur-
ance. As such, socio-economic status may act as an effect
modiﬁer. That is, these women may be more likely to use
antidepressants than those covered by private insurance pro-
grammes. This may limit the generalisation of our study, but
we feel that it does not invalidate the results.
Conclusion
The results of this study conﬁrm that either women avoid
taking antidepressants during pregnancy or physicians hesitate
prescribing them for fear of harming the fetus. Much research
has been conducted to determine the negative impact of anti-
depressants during pregnancy.H o w e v e r ,i ti si m p o r t a n tt o
assess the impact of not treating depressive symptoms and the
consequences that may result on the mother and on the new-
born. As such, more studies are needed to evaluate the impact
of the decreased use of antidepressants during pregnancy.
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